Theraclion SA (EPA:ALTHE)
France
· Delayed Price · Currency is EUR | Market Cap | 31.01M |
| Revenue (ttm) | 2.32M |
| Net Income (ttm) | -5.69M |
| Shares Out | 60.57M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 222,760 |
| Average Volume | 56,259 |
| Open | 0.513 |
| Previous Close | 0.480 |
| Day's Range | 0.500 - 0.564 |
| 52-Week Range | 0.146 - 1.250 |
| Beta | 0.18 |
| RSI | 52.25 |
| Earnings Date | Apr 16, 2026 |
About Theraclion
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient’s skin and optimize image quality. The company was incorporated in 2004 and is headquartered in Malakoff, France. [Read more]
Financial Performance
In 2025, Theraclion's revenue was 2.32 million, an increase of 179.33% compared to the previous year's 830,209. Losses were -5.69 million, -1.17% less than in 2024.
Financial StatementsNews
Theraclion’s non-invasive varicose treatment poised for FDA decision
Theraclion said 2025 marked a “decisive year”, laying the groundwork for expansion as it prepares for a potential entry into the US market.